These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Problem of neuronal reception and the dopamine hypothesis of schizophrenia]. Lideman RR; Zlobina GP; Mukhin AG Zh Nevropatol Psikhiatr Im S S Korsakova; 1980; 80(5):762-9. PubMed ID: 6106337 [No Abstract] [Full Text] [Related]
6. Dopamine in schizophrenia: a review and reconceptualization. Davis KL; Kahn RS; Ko G; Davidson M Am J Psychiatry; 1991 Nov; 148(11):1474-86. PubMed ID: 1681750 [TBL] [Abstract][Full Text] [Related]
7. Neuroleptics, dopamine, and schizophrenia. Pickar D Psychiatr Clin North Am; 1986 Mar; 9(1):35-48. PubMed ID: 2870480 [TBL] [Abstract][Full Text] [Related]
8. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia. Meltzer HY; Lee MA; Jayathilake K Neuropsychopharmacology; 2001 Mar; 24(3):278-90. PubMed ID: 11166518 [TBL] [Abstract][Full Text] [Related]
9. The two-syndrome concept and neuroendocrinology of schizophrenia. Crow TJ; Ferrier IN; Johnstone EC Psychiatr Clin North Am; 1986 Mar; 9(1):99-113. PubMed ID: 2870481 [TBL] [Abstract][Full Text] [Related]
10. Perspectives on a time-dependent model of neuroleptic action. Pickar D Schizophr Bull; 1988; 14(2):255-68. PubMed ID: 2904694 [TBL] [Abstract][Full Text] [Related]
11. Prevention of neuroleptic-induced dopamine D2 receptor supersensitivity by chronic iron salt treatment. Ben-Shachar D; Pinhassi B; Youdim MB Eur J Pharmacol; 1991 Sep; 202(2):177-83. PubMed ID: 1687031 [TBL] [Abstract][Full Text] [Related]